Sanofi: Oddo BHF maintains buy rating
(CercleFinance.com) - On Wednesday an analyst at Oddo BHF confirmed his "buy" recommendation on the Sanofi stock, appreciating positive results (on its drug candidate Avaglucosidase), even though they could have been more clear-cut.
The results of the trial justify the submission of the registration dossier in the second half of the year. The primary endpoint of non-inferiority is achieved with a significant improvement in the clinical aspect for the patient. In addition, the drug presents no specific safety features (vs. Myozyme), which should lead to approval in mid-2021, the broker says.
Oddo BHF thus confirms its target price of 103 euros for the share, meaning upside potential of 13%.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The results of the trial justify the submission of the registration dossier in the second half of the year. The primary endpoint of non-inferiority is achieved with a significant improvement in the clinical aspect for the patient. In addition, the drug presents no specific safety features (vs. Myozyme), which should lead to approval in mid-2021, the broker says.
Oddo BHF thus confirms its target price of 103 euros for the share, meaning upside potential of 13%.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.